Strategic Partnerships Oncotelic operates a capital efficient partnership model and has a majority owned joint venture (Sapu Therapeutics) that combines TGFB2 programs with next generation nanomedicine, presenting a clear pathway for co-development, risk sharing, and joint go-to-market opportunities with potential partners in biotech, pharma, and contract development/manufacturing organizations.

Clinical Momentum The company has progressed TGFB2 based therapeutics into late-stage clinical development through strategic joint ventures and has recent positive safety outcomes and European expansion in its Phase 1b program, indicating ongoing clinical momentum that can attract investors and licensing partners seeking late-stage assets.

Deciparticle Platform Deciparticle technology for intravenous formulations and its validated preclinical translational data, including ADME/PK and GLP toxicology, create a compelling value proposition for partners seeking advanced nanomedicine platforms and potential collaboration on hydrophobic or difficult-to-deliver therapies.

AI-Driven Capabilities Oncotelic’s AI driven PDAOAI platform for hypothesis generation and biomarker discovery can be leveraged in co-development deals focused on translational insights, patient stratification, and accelerated clinical decision-making, expanding opportunities for data collaboration and joint publication strategies.

Manufacturing Innovation The launch of an AI-powered GMP manufacturing platform positions the company to offer differentiated manufacturing services, enabling potential partnerships for AI-enabled digital batch records and robotic manufacturing solutions to reduce timelines and costs for partners seeking scalable production.